Fremanezumab, a medication used to prevent migraines in adults,


It is given by injection under the skin.


Trade name Ajovy.


Humanizred monoclonal antibody.


It is in the calcitonin gene-related peptide antagonist class of medications.


Target CGRP α, β (Calcitonin gene-related peptide).


Fremanezumab is a fully humanized monoclonal antibody directed against calcitonin gene-related peptides (CGRP) alpha and beta.


Pregnancy category US: N (Not classified yet).


Routes of administration Subcutaneous injection


Bioavailability 55–66%


Metabolism- Proteolysis


Elimination half-life 30–31 days.


Excretion Kidney.


Side effects: pain and redness at the site of injection. allergic reactions.


Effective in adults with four or more attacks per month.


It does not interact with other antimigraine drugs such as triptans, ergot alkaloids and analgesics. 


Can be given with a quarterly interval.


After subcutaneous injection, it has a bioavailability of 55–66%, and its highest concentrations are reached after five to seven days. 


It  is degraded by proteolysis to small peptides and amino acids, which are reused or excreted via the kidney. 


The elimination half-life is estimated to be 30 to 31 days.


Leave a Reply

Your email address will not be published. Required fields are marked *